Results 1 to 10 of about 456,969 (387)

Immunogenicity of targeted lentivectors [PDF]

open access: yesOncotarget, 2014
To increase the safety and possibly efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we recently developed the Nanobody (Nb) display technology to target LVs to antigen presenting cells (APCs).
Adotévi   +67 more
core   +9 more sources

Sleep and vaccine administration time as factors influencing vaccine immunogenicity [PDF]

open access: yesKosin Medical Journal, 2022
The immunogenicity of vaccines is affected by host, external, environmental, and vaccine factors; in addition, sleep or circadian rhythms may also have effects.
Eun Seok Kim, Chi Eun Oh
doaj   +1 more source

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations

open access: yesFrontiers in Medicine, 2022
Cell and Gene Therapy Products (CGT), regulated as Advanced Therapy Medicinal Products (ATMP) in the European Union (EU), represent a novel and varied group of biotherapeutics developed to treat specific conditions for which there are limited or no ...
Laura I. Salazar-Fontana   +2 more
doaj   +1 more source

Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells

open access: yesScientific Reports, 2021
The major histocompatibility complex II (HLA-II) facilitates the presentation of antigen-derived peptides to CD4+ T-cells. Antigen presentation is not only affected by peptide processing and intracellular trafficking, but also by mechanisms that govern ...
A. Casasola-LaMacchia   +6 more
doaj   +1 more source

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [PDF]

open access: yes, 2014
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of ...
Andersen, Peter   +20 more
core   +13 more sources

10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

open access: yesmAbs, 2020
Therapeutic proteins and emerging gene and cell-based therapies are attractive therapeutic tools for addressing unmet medical needs or when earlier conventional treatment approaches failed.
S. Tourdot   +17 more
doaj   +1 more source

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics, efficacy, and safety.
Linnea C. Franssen   +5 more
doaj   +1 more source

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

open access: yesBMC Immunology, 2021
Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany   +3 more
doaj   +1 more source

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration [PDF]

open access: yes, 2014
Strategies to optimize responses to seasonal influenza vaccination in older adults include the use of adjuvants, higher antigen doses, and intradermal delivery.
Castellino, Flora   +9 more
core   +1 more source

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

open access: yesPLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy